WO2004028480A3 - Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof - Google Patents

Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof Download PDF

Info

Publication number
WO2004028480A3
WO2004028480A3 PCT/US2003/031005 US0331005W WO2004028480A3 WO 2004028480 A3 WO2004028480 A3 WO 2004028480A3 US 0331005 W US0331005 W US 0331005W WO 2004028480 A3 WO2004028480 A3 WO 2004028480A3
Authority
WO
WIPO (PCT)
Prior art keywords
cftr
cystic fibrosis
thiazolidinone
methods
fibrosis transmembrane
Prior art date
Application number
PCT/US2003/031005
Other languages
French (fr)
Other versions
WO2004028480A2 (en
Inventor
Alan Verkman
Tonghui Ma
Original Assignee
Univ California
Alan Verkman
Tonghui Ma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/262,573 external-priority patent/US20040063695A1/en
Priority to AP2005003292A priority Critical patent/AP2005003292A0/en
Priority to EA200500583A priority patent/EA009847B1/en
Priority to JP2004540305A priority patent/JP4977319B2/en
Priority to BR0314943-9A priority patent/BR0314943A/en
Priority to EP03798805A priority patent/EP1549321A4/en
Application filed by Univ California, Alan Verkman, Tonghui Ma filed Critical Univ California
Priority to CA2500498A priority patent/CA2500498C/en
Priority to NZ538809A priority patent/NZ538809A/en
Priority to MXPA05003366A priority patent/MXPA05003366A/en
Priority to AU2003277162A priority patent/AU2003277162C1/en
Publication of WO2004028480A2 publication Critical patent/WO2004028480A2/en
Publication of WO2004028480A3 publication Critical patent/WO2004028480A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a thiazolidinone compound to a non-human animal in an amount sufficient to inhibit CFTR.
PCT/US2003/031005 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof WO2004028480A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2003277162A AU2003277162C1 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
EA200500583A EA009847B1 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
JP2004540305A JP4977319B2 (en) 2002-09-30 2003-09-30 Cystic fibrosis membrane conductance regulator protein inhibitor and method of use thereof
BR0314943-9A BR0314943A (en) 2002-09-30 2003-09-30 Cystic Fibrosis Transmembrane Conductance Regulatory Protein Inhibitors and Uses of These
EP03798805A EP1549321A4 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
AP2005003292A AP2005003292A0 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
CA2500498A CA2500498C (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
NZ538809A NZ538809A (en) 2002-09-30 2003-09-30 Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
MXPA05003366A MXPA05003366A (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/262,573 US20040063695A1 (en) 2002-09-30 2002-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US10/262,573 2002-09-30
US48025303P 2003-06-20 2003-06-20
US60/480,253 2003-06-20

Publications (2)

Publication Number Publication Date
WO2004028480A2 WO2004028480A2 (en) 2004-04-08
WO2004028480A3 true WO2004028480A3 (en) 2004-07-01

Family

ID=32044981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031005 WO2004028480A2 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Country Status (13)

Country Link
EP (1) EP1549321A4 (en)
JP (1) JP4977319B2 (en)
KR (1) KR20050061501A (en)
CN (1) CN100356922C (en)
AP (1) AP2005003292A0 (en)
AU (1) AU2003277162C1 (en)
BR (1) BR0314943A (en)
CA (1) CA2500498C (en)
EA (1) EA009847B1 (en)
MX (1) MXPA05003366A (en)
NZ (1) NZ538809A (en)
PL (1) PL376147A1 (en)
WO (1) WO2004028480A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952049B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
ES2554353T3 (en) 2006-04-07 2015-12-18 Vertex Pharmaceuticals Incorporated Conveyor modulators of the ATP binding cassette
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008121877A2 (en) 2007-04-02 2008-10-09 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
JP5389030B2 (en) * 2007-08-24 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド Isothiazolopyridinone useful for the treatment of (especially) cystic fibrosis
NZ585980A (en) 2007-11-16 2012-04-27 Vertex Pharma Isoquinoline modulators of atp-binding cassette transporters
CA2706920C (en) 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2009228307A1 (en) * 2008-03-25 2009-10-01 The Regents Of The University Of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
NZ588006A (en) 2008-03-31 2012-08-31 Vertex Pharma Pyridine derivatives as CFTR modulators, in particular N-(6-(benzylamino)-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamide
WO2009131951A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2490696A1 (en) * 2009-10-20 2012-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
CA3016080C (en) 2010-03-25 2019-08-20 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2579965T3 (en) 2010-04-07 2016-08-17 Vertex Pharmaceuticals Incorporated Solid forms of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropane carboxamide) -3-methylpyridin-2-yl) benzoic
BR112012026255A2 (en) 2010-04-07 2017-03-14 Vertex Pharma 3- (6- (1- (2-, 2-Difluorbenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid pharmaceutical compositions and administration thereof
JP2013525371A (en) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド Method for producing cycloalkylcarboxamide-indole compound
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
BR112013004443A8 (en) 2010-08-23 2018-01-02 Vertex Pharma (r) -1- (2,2-difluorbenzo [d] [1,3] dioxol-5-yl) -n- (1- (2,3-dihydroxypropyl) -6-fluoro-2 pharmaceutical compositions - (1-hydroxy-2-methylpropan-2-yl) -1h-indol-5-yl) cyclopropane carboxamide and administration thereof
CN102133402B (en) * 2011-03-24 2013-06-12 首都医科大学附属北京同仁医院 Application of cystic fibrosis transmembrane transduction regulating factor inhibitor to preparation of medicaments for treating diabetes
US9056862B2 (en) 2011-05-10 2015-06-16 National University Corporation Kobe University Thioxothiazolidine derivative having Ras function inhibitory effect
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
RU2644723C2 (en) 2012-01-25 2018-02-13 Вертекс Фармасьютикалз Инкорпорейтед Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzonic acid
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CA2890106C (en) 2012-11-02 2022-08-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
FR2999191B1 (en) 2012-12-12 2016-02-05 Lesaffre & Cie PROBIOTIC STRAINS FOR THE TREATMENT AND / OR PREVENTION OF DIARRHEA
DK3424534T3 (en) 2014-04-15 2021-07-26 Vertex Pharma PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY CYSTIC FIBROSET TRANSMISSION PIPE REGULATOR
MA54649A (en) 2014-10-06 2022-04-27 Vertex Pharma CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS
CN104398509B (en) * 2014-11-13 2017-01-11 四川大学华西第二医院 Application of CFTR (cystic fibrosis transmembrane conductance regulator) inhibitor CFTRinh-172 in preparation of drug for prevention and treatment of leukemia cell mediated diseases
CN104788423B (en) * 2015-03-13 2016-10-26 成都理工大学 A kind of new cystic fibrosis transmembrane conductance regulator inhibitor
PT3394083T (en) 2015-12-24 2021-12-07 Univ California Cftr regulators and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96654A (en) * 1989-12-21 1995-06-29 Lilly Co Eli Hydroxybenzyl substituted sulfur containing heterocyclic derivatives their preparation and pharmaceutical compositions containing them
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (en) * 1996-09-30 2003-05-15 Пфайзер Інк. Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method
ID27787A (en) * 1998-08-21 2001-04-26 Viro Pharma Inc COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES
US6484397B1 (en) * 2000-07-11 2002-11-26 Corning Incorporated Method of assembling a catalytic converter for use in an internal combustion engine
US20020052396A1 (en) * 2001-04-23 2002-05-02 Bailey Thomas R. Compounds, compositions and methods for treating or preventing viral infections and associated diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [online] GUPTA S.P. ET AL.: "Synthesis and fungitoxicity of some 5-sustituted 3-poly(nitrophenyl)rhodanines", XP002976975, accession no. STN Database accession no. 1978:597389 *
DATABASE HCAPLUS [online] MA T. ET AL.: "Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion", XP002976974, accession no. STN Database accession no. 2002:932809 *
DATABASE HCAPLUS [online] ROMAN O.M. ET AL.: "Synthesis and antiinflammatory activity of 3-aryl-5-arylidene-2-thioxothiazolidine-4-ones", XP002976976, accession no. STN Database accession no. 2002:664146 *
FARMATSEVTICHNII ZHURNAL (KIEV), vol. 3, 2002, pages 56 - 59 *
JOURNAL OF CLINICAL INVESTIGATION, vol. 110, no. 11, 2002, pages 1651 - 1658 *
JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 55, no. 5, 1978, pages 483 - 485 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952049B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8952050B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters

Also Published As

Publication number Publication date
EP1549321A4 (en) 2007-05-23
NZ538809A (en) 2008-06-30
JP4977319B2 (en) 2012-07-18
MXPA05003366A (en) 2005-10-05
BR0314943A (en) 2005-08-02
CN100356922C (en) 2007-12-26
EA009847B1 (en) 2008-04-28
WO2004028480A2 (en) 2004-04-08
EA200500583A1 (en) 2005-12-29
PL376147A1 (en) 2005-12-27
CN1684686A (en) 2005-10-19
CA2500498C (en) 2012-08-21
JP2006503853A (en) 2006-02-02
AU2003277162A1 (en) 2004-04-19
CA2500498A1 (en) 2004-04-08
AU2003277162B2 (en) 2009-07-16
AU2003277162C1 (en) 2009-12-24
EP1549321A2 (en) 2005-07-06
KR20050061501A (en) 2005-06-22
AP2005003292A0 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2004028480A3 (en) Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2005094374A3 (en) Hydrazide-containing cftr inhibitor compounds and uses thereof
CA2566301A1 (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
WO2007126964A3 (en) Kinase inhibitors
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
NO20053077L (en) Therapeutic formulations for the treatment of beta-amyloid-related diseases.
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
US6683054B1 (en) Use of melagatran
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
EP1666064A4 (en) Remedy for diseases associated with immunoglobulin gene translocation
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
JP4812394B2 (en) Analgesic composition
CA2648751A1 (en) Use of aminapthone for the preparation of a medicament for treating arteriopathies
US20040023937A1 (en) Anti-cancer formulation
US20070208080A1 (en) A composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
WO2005020968A3 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
JP4221267B2 (en) Drugs to suppress itching
ATE477021T1 (en) 1,3,5-TRIAZEPINE DIONE FOR THE TREATMENT OF MALARIA
HUP0303754A2 (en) Use of radical scavenging compounds for preparation of pharmaceutical compsoition suitable for treatment and prevention of no-dependent microcirculation disorders
Alqurashi et al. Protective effect of sterubin against neurochemical and behavioral impairments in rotenone-induced Parkinson's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 167362

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 538809

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005/02517

Country of ref document: ZA

Ref document number: 2500498

Country of ref document: CA

Ref document number: 520/KOLNP/2005

Country of ref document: IN

Ref document number: 200502517

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020057005551

Country of ref document: KR

Ref document number: 20038233665

Country of ref document: CN

Ref document number: 1-2005-500625

Country of ref document: PH

Ref document number: 2004540305

Country of ref document: JP

Ref document number: 376147

Country of ref document: PL

Ref document number: PA/a/2005/003366

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003277162

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: AP/P/2005/003292

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 2003798805

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200500583

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1200500594

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020057005551

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003798805

Country of ref document: EP